Vaxon Biotech successfully completes its Phase I/II trial of Vx-001 cancer vaccine
Phase III ready to start in NSCLC
21-May-2010 -
Vaxon Biotech announced the successful conclusion of the Phase I/II trial of its Vx-001 therapeutic cancer vaccine. As a result, Vaxon is pursuing the clinical development of Vx-001 by launching a pivotal phase III trial in non-small cell lung cancer (NSCLC) in 2010, and in hepatocellular ...
breast cancer
hepatocellular carcinoma
lung cancer
+3